AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2022
Dec 5, 2022
33483_dirs_2022-12-05_93067766-0fe6-4c73-ac30-4dab26d3dcfa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-12-01
Reporting Person: Brunn Carsten (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-01 | Common Stock | M | 10938 | — | Acquired | 548805 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-01 | Restricted Stock Units | $ | M | 10938 | Disposed | Common Stock (10938.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: This restricted stock unit award is fully vested and has no expiration date
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8